Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. As a biotechnology company developing and commercializing therapies for gastrointestinal (GI) and rare diseases, Ironwood uses these filings to report on its financial condition, collaboration revenues from LINZESS® (linaclotide), progress of its apraglutide program, capital structure and risk factors.
In its annual reports on Form 10-K, Ironwood presents audited financial statements, management’s discussion and analysis of results, details on its GI and rare disease portfolio, and information about collaborations with partners such as AbbVie, Astellas and AstraZeneca. These filings also describe material weaknesses in internal control over financial reporting identified as of December 31, 2024, and the company’s efforts to address them.
Quarterly reports on Form 10-Q update investors on interim financial performance, including collaboration revenue tied to LINZESS U.S. net sales, research and development expenses related to apraglutide and other programs, restructuring charges, interest expense on convertible senior notes and revolving credit facilities, and non-GAAP measures such as adjusted EBITDA and non-GAAP net income or loss.
Current reports on Form 8-K provide timely disclosure of specific events. For Ironwood, 8-K filings in 2025 have covered topics such as Nasdaq notifications about bid price and filing timeliness, the company’s receipt of a Maximum Fair Price determination for LINZESS under the Inflation Reduction Act, changes in the independent registered public accounting firm, director resignations, and the public release of quarterly earnings press releases.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, such as shifts in financial guidance, updates on the apraglutide regulatory path, or changes in collaboration economics. Users can quickly identify information related to annual reports (10-K), quarterly reports (10-Q) and current reports (8-K), and can review disclosures that affect listing status, internal controls, and major GI and rare disease programs.
This page also helps investors monitor governance and compliance developments, including responses to Nasdaq listing rules and auditor changes, alongside the financial and operational data that shape the IRWD investment profile.
Ironwood Pharmaceuticals, Inc. submitted a Form 144 notice reporting proposed sales of Class A Common Stock tied to previously granted restricted stock unit awards. The excerpt lists example lots of 20,362, 17,467, 13,606, and 33,334 shares associated with award grant dates from 03/02/2022 through 02/10/2025.
Ironwood Pharmaceuticals, Inc. submitted a Form 144 proposing resale of Class A common stock derived from restricted stock unit awards. The filing lists grant-dated lots of shares awarded on 03/02/2022, 03/08/2023, 02/12/2024, and 02/10/2025.
The excerpt includes per-lot quantities, including 16,969 and 16,375 shares as examples; these lots are described as restricted stock unit awards under the company's equity incentive plan. Timing and aggregate resale proceeds are not provided in the excerpt.
Ironwood Pharmaceuticals reported proposed sales of Class A common stock via a Form 144 tied to restricted stock unit awards, including awards of 62,218 (03/08/2022), 80,198 (03/08/2023), 88,292 (03/05/2024) and 180,000 (05/20/2025) shares.
Each listed award was granted under the Issuer's 2019 Equity Incentive Plan or its amended and restated 2019 Equity Incentive Plan. The filing lists the securities and grant dates associated with the proposed sales.
Ironwood Pharmaceuticals reports a 9.85% beneficial stake held by Armistice Capital and Steven Boyd. The filing shows 16,025,000 shares of Class A common stock as beneficially owned as of 12/31/2025, with 16,025,000 shares of shared voting power and shared dispositive power.
The statement filed jointly and signed 02/17/2026 attributes ownership to Armistice Capital as investment manager of Armistice Capital Master Fund Ltd.; the Master Fund is identified as the direct holder.
Ironwood Pharmaceuticals officer Ronald Silver reported a planned stock sale. On January 5, 2026, he sold 35,416 shares of Ironwood Class A Common Stock at $4.60 per share in a transaction coded as a sale. The filing states this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Silver, which is designed to allow insiders to sell shares according to a set schedule. After this transaction, he beneficially owned 276,809 shares of Ironwood stock, held directly. A footnote explains that the 35,416 shares sold had been acquired under Ironwood’s employee stock purchase plan on December 31, 2025.
Ironwood Pharmaceuticals insider activity: A reporting person associated with Ironwood Pharmaceuticals received an award of 4,178 shares of Class A common stock on 12/15/2025 at a price of $0 per share. The filing states this grant was issued under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
After this transaction, the reporting person directly beneficially owns 251,858 Class A shares and indirectly beneficially owns 15,919,435 Class A shares through Sarissa Capital Management LP and related funds, reflecting both personal and fund-related positions in IRONWOOD PHARMACEUTICALS INC (IRWD).
Ironwood Pharmaceuticals reported that the U.S. Department of Health and Human Services has set the Medicare “Maximum Fair Price” for LINZESS (linaclotide) at $136 for a 30-day equivalent supply. This Maximum Fair Price will become the new Medicare net price starting January 1, 2027 under the Inflation Reduction Act of 2022.
The company states that this revised price for LINZESS is in line with its expectations, indicating the decision aligns with its planning around the product’s U.S. Medicare pricing.
Ironwood Pharmaceuticals Inc. (IRWD) reported an insider transaction by its Chief Commercial Officer. On 11/17/2025, the officer sold 6,016 shares of Class A common stock at $3.32 per share. According to the disclosure, this sale was made automatically to cover tax withholding obligations arising from the vesting of restricted stock units and was not a discretionary trade. After this transaction, the officer beneficially owned 235,264 shares of Ironwood common stock.
Ironwood Pharmaceuticals (IRWD) furnished an Item 2.02 Form 8-K announcing a press release with an update on recent business activities and results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference. The information is furnished, not filed, under the Exchange Act.
Ironwood Pharmaceuticals (IRWD) reported stronger Q3 2025 results. Total revenues were $122.1 million, up from $91.6 million a year ago, driven mainly by collaborative revenue from the LINZESS partnership with AbbVie in North America ($120.5 million). Operating income rose to $75.5 million from $25.6 million, and net income improved to $40.1 million versus $3.6 million, with diluted EPS of $0.23.
Expenses declined year over year, with research and development at $22.5 million and selling, general and administrative at $21.9 million; restructuring expense was $2.2 million. Cash and cash equivalents increased to $140.4 million, supported by $52.5 million net cash from operating activities for the nine-month period. The company reported a current portion of convertible senior notes of $199.5 million and $385.0 million outstanding on its revolving credit facility. As of October 31, 2025, 162,678,647 Class A shares were outstanding.
For the first nine months of 2025, revenues were $248.4 million and net income was $26.3 million, reflecting improved profitability compared to the prior-year period.